The data from CD10 was sufficient for EUA. The que
Post# of 148177
It seems that communicate from fda in that indication remains unclear, with interest in antivirals and vaccines, with therapy desired by them only for severe.
It is a bit of a reach imo to hold NP accountable for the shifting fda expectations.
This is one area where I believe his communication was as timely as expected as Cytodyn was not given any concrete direction from fda in m/m.